Literature DB >> 6258365

Simultaneous bilateral cancer of the brease--evaluation of the use of a contralateral biopsy.

L I Andersen, O Muchardt.   

Abstract

During a five-year period 299 female patients with breast cancer were treated by mastectomy. In 170 of the patients a biopsy of the contralateral upper lateral quadrant was performed during the operation. In 164 of the patients with primary carcinoma of ductal origin only 7 cases of malignancy in the contralateral biopsy were observed. In six females (3.5%) the primary cancer was of lobular origin and in three of these patients (50%) the contralateral biopsies showed lobular carcinoma in situ (LCIS). It is concluded that random contralateral biopsies of the breast should be restricted to patients with a primary cancer of lobular origin.

Entities:  

Mesh:

Year:  1980        PMID: 6258365

Source DB:  PubMed          Journal:  Acta Chir Scand        ISSN: 0001-5482


  5 in total

1.  The role of mammography in the detection of bilateral primary breast cancer.

Authors:  J G Tinnemans; T Wobbes; J H Hendriks; R Holland; R F Van der Sluis; H H De Boer
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

Review 2.  Routine contralateral breast biopsy: helpful or irrelevant? Experience in 871 patients, 1979-1993.

Authors:  H S Cody
Journal:  Ann Surg       Date:  1997-04       Impact factor: 12.969

3.  The clinical management of a normal contralateral breast in patients with lobular breast cancer.

Authors:  R R Baker; F P Kuhajda
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

4.  Bilateral breast cancer. Risk reduction by contralateral biopsy.

Authors:  H J Wanebo; G M Senofsky; R E Fechner; D Kaiser; S Lynn; J Paradies
Journal:  Ann Surg       Date:  1985-06       Impact factor: 12.969

5.  Evaluation of the contralateral breast. The role of biopsy at the time of treatment of primary breast cancer.

Authors:  B L Smith; M Bertagnolli; B B Klein; S Batter; M Chang; L M Douville; T J Eberlein
Journal:  Ann Surg       Date:  1992-07       Impact factor: 12.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.